Skip to content

Stereotaxis STXS Allowance for doubtful accounts

Allowance for doubtful accounts at other companies

Abbott logo
AbbottABT
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
ITG
Integer HoldingsITGR
iRadimed logo
iRadimedIRMD
IAR
Integra LifeSciencesIART

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's allowance for doubtful accounts?
Stereotaxis (STXS) reported allowance for doubtful accounts of $630K in Q1 2026.
How has Stereotaxis's allowance for doubtful accounts changed year-over-year?
Stereotaxis's allowance for doubtful accounts increased by 13.3% year-over-year, from $556K to $630K.
What is the long-term trend for Stereotaxis's allowance for doubtful accounts?
Over 5 years (2020 to 2025), Stereotaxis's allowance for doubtful accounts has grown at a 34.3% compound annual growth rate (CAGR), from $123.61K to $541K.